(3Z)-3-(1,3-benzothiazol-6-ylimino)-1-phenyl-1,3-dihydro-2H-indol-2-one | 445455-28-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: (3Z)-3-(1,3-benzothiazol-6-ylimino)-1-phenyl-1,3-dihydro-2H-indol-2-one
• CAS: 445455-28-7
• 化学式: C₂₁H₁₃N₃OS
• 分子量: 355.42
• InChiKey: SEMSITQHUNJBHI-ATJXCDBQSA-N

物化性质

• 沸点：
  558.8±42.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  26.0
• 可旋转键数：
  2.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.56
• 氢给体数：
  0.0
• 氢受体数：
  4.0

文献信息

• Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
  申请人：——

  公开号：US20030078271A1

  公开（公告）日：2003-04-24

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

  这项发明涉及嘧啶和吲哚酮衍生物，它们是选择性GAL3受体拮抗剂。该发明提供了一种包含该发明化合物的治疗有效量和药用载体的药物组合物。该发明还提供了通过结合该发明化合物的治疗有效量和药用载体制备的药物组合物。该发明进一步提供了一种制备药物组合物的方法，包括结合该发明化合物的治疗有效量和药用载体。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者施用足以治疗受试者抑郁症和/或焦虑症的该发明化合物的量。该发明还提供了一种治疗受试者抑郁症和/或焦虑症的方法，包括向受试者施用包含药用载体和治疗有效量GAL3受体拮抗剂的组合物。
• GAL3 antagonists for the treatment of neuropathic pain
  申请人：——

  公开号：US20040092570A1

  公开（公告）日：2004-05-13

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor and are useful for the treatment of neuropathic pain and other abnormalities. This invention also provides a method of treating a subject suffering from an abnormality which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's abnormality. This invention also provides a method of treating an abnormality in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

  这项发明涉及嘧啶和吲哚酮衍生物，它们是选择性的GAL3受体拮抗剂，可用于治疗神经病痛和其他异常。这项发明还提供了一种治疗患有异常的受试者的方法，包括向受试者投予本发明中的化合物的有效剂量以治疗受试者的异常。这项发明还提供了一种治疗受试者异常的方法，包括向受试者投予包含药用载体和治疗有效量的GAL3受体拮抗剂的组合物。
• Indolone compounds useful to treat cognitive impairment
  申请人：Blackburn P. Thomas

  公开号：US20070135509A1

  公开（公告）日：2007-06-14

  This invention provides a method of treating a subject suffering from a cognitive impairment or a cognitive disorder which comprises administering to the subject an amount of an indolone compound effective to treat the subject's cognitive impairment or disorder.

  这项发明提供了一种治疗患有认知障碍或认知障碍的受试者的方法，包括向受试者施用一定量的吲哚酮化合物，以有效治疗受试者的认知障碍或障碍。
• Indolone Compounds Useful To Treat Cognitive Impairment
  申请人：Blackburn P. Thomas

  公开号：US20070135510A1

  公开（公告）日：2007-06-14

  This invention provides a method of treating a subject suffering from a cognitive impairment or a cognitive disorder which comprises administering to the subject an amount of an indolone compound effective to treat the subject's cognitive impairment or disorder.

  该发明提供了一种治疗患认知障碍或认知障碍的受试者的方法，包括向受试者施用有效治疗受试者认知障碍或障碍的吲哚酮化合物的剂量。
• Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
  申请人：——

  公开号：US20040102507A1

  公开（公告）日：2004-05-27

  This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.

  这项发明涉及对GALR3受体的拮抗剂，即吲哚酮衍生物。该发明提供了一种包含本发明化合物的治疗有效量和药用可接受载体的药物组合物。此外，该发明还提供了一种由结合本发明化合物的治疗有效量和药用可接受载体制成的药物组合物。该发明进一步提供了一种制备药物组合物的方法，包括结合本发明化合物的治疗有效量和药用可接受载体。